Sharing the work being done by MOHCCN researchers across Canada

MOHCCN Seminar Series

This seminar series features virtual talks from MOHCCN research partner investigators and trainees, providing a platform for MOHCCN members to share their ongoing work in precision oncology with the wider Network. These seminars will be of interest primarily to cancer researchers, clinicians, trainees, and members of the MOHCCN Patient Working Group across the country.

Upcoming seminars

Next: Thursday, April 25th 2024 - Marathon of Hope - Québec (MOH-Q)

3:30pm NT / 3pm AT / 2pm ET / 1pm CT / 12pm MT / 11am PT

REGISTER NOW!

 

Agenda

MOH-Q consortium activities update

Anne-Marie Mes-Masson, PhD, FRSC, FCAHS - Professor, Department of Medicine, Université de Montréal; Associate Scientific Director, Basic and Translational Research, Centre de recherche du Centre hospitalier de l'Université de Montréal (CR-CHUM); MOHCCN consortium lead (MOH-Q)

Morag Park, CQ, PhD, FRSC, FCAHS - Distinguished James McGill Professor, Departments of Oncology, Biochemistry, and Medicine, McGill University; Diane and Sal Guerrera Chair in Cancer Genetics; Director, Rosalind and Morris Goodman Cancer Institute, McGill University; MOHCCN consortium lead (MOH-Q)

 
Research presentations

Role of gut and intratumoral microbiota on response to immune checkpoint inhibitors in lung cancer and melanoma

Arielle Elkrief, MD, FRCPC - Assistant Professor, Department of Hematology-Oncology, Université de Montréal; Medical Director, CHUM Microbiome Centre; MOHCCN cohort lead

View abstract and plain language summary

 

Using unsupervised clustering of multiomic data to define molecular and transcriptional subtypes of rare pancreatic neuroendocrine tumours

Joan Miguel Romero, MSc - MD-PhD Candidate, Division of Experimental Medicine, Rosalind and Morris Goodman Cancer Institute and Research Institute of the McGill University Health Centre (RI-MUHC), McGill University

View abstract and plain language summary

 

This event will be co-chaired by Natalie Kwadrans, BSc, MBA, CPA-CMA, de novo stage 4 breast cancer patient and MOHCCN Patient Working Group member, and Véronique LeBlanc, PhD, Program Manager and Scientific Writer, MOHCCN.

 

 

The remaining 2024 MOHCCN seminars are tentatively scheduled for the following dates:

June 27: British Columbia Cancer Consortium (BC2C)

September 26: Prairies Cancer Consortium (PR2C)

October 31: Atlantic Cancer Consortium (ACC)

November 28: Pan-Canadian projects

 

 

Previous seminars

2024

MOHCCN Seminar Series: Princess Margaret Cancer Consortium

Thursday, February 29 2024

 

PM2C CONSORTIUM ACTIVITIES UPDATE

Dr. Lillian Siu - Medical Oncologist, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN); MOHCCN consortium lead (PM2C)

Dr. Amber Simpson - Associate Professor, Queen's University; Canada Research Chair in Biomedical Computing and Informatics; MOHCCN Kingston / Queen's University institutional lead

RESEARCH PRESENTATIONS

Identification and clinical implications of circular RNA in cancer

Dr. Hansen He - Senior Scientist, PMCC, UHN; Professor, Department of Medical Biophysics, University of Toronto; MOHCCN cohort lead

View abstract and plain language summary

Shedding light on the surge: Investigating the etiology of young onset colorectal cancer

Dr. Kevin Wang - Medical Oncology Fellow, Eliot Phillipson Clinician-Scientist Training Program, PMCC, UHN

View abstract and plain language summary

 

 

2022

MOHCCN Seminar Series: Atlantic Cancer Consortium

Monday, June 6 2022

Presenters

  • “Transforming the data ecosystem for precision oncology research and care” Dr. Robin Urquhart, PhD. Associate Professor, Department of Community Health and Epidemiology, Dalhousie University Nova Scotia Lead/PI for the Atlantic Cancer Consortium
  • “Clinical and social patient outcomes and their predictors” Dr. Sevtap Savas, PhD. Professor, Division of Biomedical Sciences, Faculty of Medicine, Memorial University
  • “Small RNA in extracellular vesicles (EVs) of GBM, grade 4 astrocytoma recurrence” Dr. Jeremy Roy, PhD. Scientist, Atlantic Cancer Research Institute. Adjunct (Scholar) Professor, Department of Medical Neuroscience, Dalhousie University Associate Member, Beatrice Hunter Cancer Research Institute and Dr. Adrienne Weeks, MD PhD. Assistant Professor, Division of Neurosurgery, Faculty of Medicine, Dalhousie University Atlantic Canada Research Institute and Dalhousie University
  • “Applying omics and bioinformatics to investigate novel mediators of breast cancer progression” Marie-Claire Wasson. PhD Candidate, Department of Pathology, Faculty of Medicine, Dalhousie University Trainee, Cancer Research Training Program, Beatrice Hunter Cancer Research Institute

MOHCCN Seminar Series: Marathon of Hope - Québec

Monday, February 7 2022


Presenters

  • Natasha Szuber, MD M.Sc. FRCPC “Advances in myeloproliferative neoplasms”
  • Sonia del Rincón, PhD “Targeting MNK1/2 in cancer: What have we learned and where are we going?”
  • Yacine Bareche, PhD “Leveraging big data of immune checkpoint blockade response identifies novel potential targets”
  • Ian Watson, PhD “The spatial immune landscape of melanoma”

 

2021

MOHCCN Seminar Series: Precision Medicine Initiatives at the Princess Margaret Cancer Centre Consortium

Monday, December 6 2021

 

Presenters

  • Dr. Lillian Siu
  • Dr. Phillippe Bedard
  • Dr. Alberto Hernando Calvo

MOHCCN Seminar Series: TFRI's EPPIC Program

Monday, October 4 2021

Keynote

  • Dr. Daniel Renouf, MD, MPH, FRCPC, presenting Precision Medicine in Pancreatic Cancer: The TFRI EPPIC Program

Presenters

  • Dr. Yifan Wang, MD, PhD (candidate), presenting Informing pancreatic cancer care through ambulatory oncology clinic-based germline testing models and precision medicine

  • James Topham (BC Genome Sciences Centre) and Erica Tsang (BC Cancer) presenting KRAS WT Pancreatic Cancer

Moderator

  • Dr. George Zogopoulos, MD, PhD, FRCS(C), FACS. Associate Professor of Surgery and Oncology, McGill University and Scientist, Research Institute of the McGill University Health Centre and Rosalind and Morris Goodman Cancer Institute